Key Developments: - Shanghai Industrial Holdings (00363): Shanghai Huashi and SIIC Urban Development's Shanghai Healthcare Management to sell 49% stake in Shanghai SIIC Medical Beauty Hospital for RMB 73.598 million. - Hengrui Pharmaceuticals (01276): Receives clinical trial approval for Ruiweiluamine tablets. - CanSino Biologics (06185): Initiates Phase I clinical trial for inhaled TB booster vaccine in Indonesia, enrolling first participant. - Zhonghui Biotech-B (02627): Launches Phase I trials for quadrivalent and trivalent influenza subunit vaccines (adjuvanted). - Cloud Healthy (09955) signs service agreement with JD Health (06618) to expand online sales and services for Livzonmin® and other P2M pipeline products. - China Resources Land (01109) plans placement of CR Mixc Lifestyle (01209) shares to diversify shareholder structure. - Shougang Century Holdings (00697): Beijing Robotics Fund invests in Xingdong Jiyuan.

Operational Performance: - Tencent Holdings (00700) posts Q3 revenue and profit growth, with non-IFRS net profit at RMB 70.551 billion, driven by Hunyuan model. - JD-SW (09618) reports Q3 total revenue of RMB 299.059 billion, up 14.85% YoY. - JD Logistics (02618) achieves Q3 revenue of RMB 55.084 billion, up 24.1% YoY. - JD Health (06618) records Q3 operating profit of RMB 1.243 billion, surging 125.3% YoY. - SMIC (00981) posts Q3 net profit of $192 million, up 44.7% QoQ and 28.9% YoY. - Bilibili-W (09626) turns profitable with Q3 net income of RMB 469 million, setting new user metric highs. - China Pacific Insurance (02601): CPIC Life Insurance’s premium income rises 9.9% YoY to RMB 241.322 billion in Jan-Oct.